Stereoselective metabolism of ifosfamide by human P-450S 3A4 and 2B6. Favorable metabolic properties of R-enantiomer

Drug Metabolism and Disposition

Volumn 27, Issue 11, 1999, Pages 1309-1318

  Roy, Partha ^a   Tretyakov, Olga ^b   Wright, Joel ^b   Waxman, David J ^a  

^a Boston University   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450; DRUG METABOLITE; IFOSFAMIDE; MONOCLONAL ANTIBODY;

ARTICLE; DRUG METABOLISM; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYDROXYLATION; PRIORITY JOURNAL; STEREOCHEMISTRY;

ANTINEOPLASTIC AGENTS, ALKYLATING; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; HUMANS; IFOSFAMIDE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT PROTEINS; STEREOISOMERISM;

ANIMALIA;

EID: 0032708116     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Berger DP, Fiebig HH, Winterhalter BR, Wallbrecher E and Henss H (1990) Preclinical phase II study of ifosfamide in human tumour xenografts in vivo. Cancer Chemother Pharmacol 26:S7-S11.
2. Boddy AV, Proctor M, Simmonds D, Lind MJ and Idle JR (1995a) Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 31:A69-A76.
3. Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD and Idle JR (1995b) Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 31: A785-A790.
4. Bohnenstengel F, Eichelbaum M, Golbs E and Kroemer HK (1997) High-performance liquid chromatographic determination of acrolein as a marker for cyclophosphamide bioactivation in human liver microsomes. J Chromatogr B Biomed Sci Appl 692:163-168.
5. Boos J, Welslau U, Ritter J, Blaschke G and Schellong G (1991) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28:455-460.
6. Brain EG, Yu LJ, Gustafsson K, Drewes P and Waxman DJ (1998) Modulation of P450-dependent ifosfamide pharmacokinetics: A better understanding of drug activation in vivo. Br J Cancer 77:1768-1776.
7. Bunting KD and Townsend AJ (1996) Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytoloxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. J Biol Chem 271:11891-11896.
8. m catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 7:211-221.
9. Chang TK, Yu L, Maurel P and Waxman DJ (1997b) Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 57:1946-1954.
10. Chang TKH, Gonzalez FJ and Waxman DJ (1994) Evaluation of triacetyloleandomycin, alphanaphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437-442.
11. Chang TKH, Weber GF, Crespi CL and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637.
12. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK and Waxman DJ (1997) Human cytochrome P4502B6: Inlerindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985-993.
13. de Kraker J and Voute PA (1989) Experience with ifosfamide in paediatric tumours. Cancer Chemother Pharmacol 24:S28-S29.
14. Dirven HA, Megens L, Oudshoorn MJ, Dingemanse MA, van Ommen B and van Bladeren PJ (1995) Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem Res Toxicol 8:979-986.
15. Farmer PB (1988) Enantiomers of cyclophosphamide and iphosphamide. Biochem Pharmacol 37:145-148.
16. Fleming RA (1997) An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17:146S-154S.
17. Goren MP, Wright RK, Pratt CB and Pell FE (1986) Dechloroethylation of ifosfamide and neurotoxicity [letter]. Lancet 2:1219-1220.
18. Granvil CP, Ducharme J, Leyland-Jones B, Trudeau M and Wainer IW (1996a) Stereoselective pharmacokinetics of ifosfamide and its 2-and 3-N-dechloroethylated metabolites in female cancer patients. Cancer Chemother Pharmacol 37:451-456.
19. Granvil CP, Madan A, Sharkawi M, Parkinson A and Wainer IW (1999) Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)-and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 27:533-541.
20. Granvil CP, Sharkawi M, Ducharme J, Madan A, Sanzghiri U, Parkinson A and Wainer IW (1996b) Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of ifosfamide enantiomers by human liver microsomes. ISSX Proc 10:360.
21. Granvil CP, Wang T, Batist G and Wainer IW (1994) Influence of phenobarbital induction on the enantioselective N-dechloroethylation of ifosfamide enantiomers in the rat. Drug Metab Dispos 22:165-167.
22. Granville CP, Gehrcke B, Konig WA and Wainer IW (1993) Determination of the enantiomers of ifosfarnide and its 2-and 3-N-dechloroethylated metabolites in plasma and urine using enantioselective gas chromatography with mass spectrometric detection. J Chromatogr 622: 21-31.
23. Hickman D, Wang JP, Wang Y and Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207-215.
24. Hilgard P, Herdrich K and Brade W (1983) Ifosfamide-current aspects and perspectives. Cancer Treat Rev 10 (Suppl A):183-192.
25. Huang Z, Roy P and Waxman DJ (1999) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol, in press.
26. Huang Z and Waxman DJ (1999) HPLC-fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anti-cancer drug ifosfamide, in plasma and in liver microsomal incubations. Analyt Biochem 273:117-125.
27. Kivisto KT and Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37:40S-48S.
28. Kurowski V and Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2-and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36-42.
29. Lokiec F, Santoni J, Weill S and Tubiana-Hulin M (1996) Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. Anticancer Drugs 7:893-896.
30. Lu H, Wang JJ, Chan KK and Young D (1998) Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats. Drug Metab Dispos 26:476-482.
31. Martino R, Crasnier F, Chouini-Lalanne N, Gilard V, Niemeyer U, De Forni M and Malet-Martino MC (1992) A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy. J Pharmacol Exp Ther 260:1133-1144.
32. Masurel D, Houghton PJ, Young CL and Wainer IW (1990) Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice. Cancer Res 50:252-255.
33. Maurel P (1996) The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv Drug Delivery Rev 22:105-132.
34. Misiura K, Okruszek A, Pankiewicz K, Stec WJ, Czownicki Z and Utracka B (1983) Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine. J Med Chem 26:674-679.
35. Nithipatikom K, Mizumura T and Gross GJ (1994) Determination of plasma adenosine by high-performance liquid chromatography with column switching and fluorometric detection [published erratum appears in 1995 Anal Biochem 225:380]. Anal Biochem 223:280-284.
36. Pohl J, Stekar J and Hilgard P (1989) Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication. Arzneim-Forsch 39:704-705.
37. Prasad VK, Corlett SA, Abaasi K, Heney D, Lewis I and Chrystyn H (1994) Ifosfamide enantiomers: Pharmacokinetics in children. Cancer Chemother Pharmacol 34:447-449.
38. Roy P, Yu LJ, Crespi CL and Waxman DJ (1999) Development of a substrate-activity based approach to identify the major human liver P450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P450 profiles. Drug Metab Dispos 27:655-666.
39. Shimada T, Yamazaki H, Miraura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
40. Sladek NE (1994) Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines, in Anticancer Drugs: Reactive Metabolism and Interactions (Powers G ed) pp 79-156, Pergamon Press, Oxford, UK.
41. Wainer IW, Ducharme J and Batist G (1995) "Ifosfamide: should the honeymoon be over?": A two-dimensional question for a three-dimensional problem [letter; comment]. J Clin Oncol 13:1824-1826.
42. Wainer IW, Ducharme J and Granvil CP (1996) The N-dechloroethylation of ifosfamide: Using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Cancer Chemother Pharmacol 37:332-336.
43. Wainer IW, Ducharme J, Granvil CP, Trudeau M and Leyland-Jones B (1994a) Ifosfamide stereoselective dichloroethylation and neurotoxicity [letter]. Lancet 343:982-983.
44. Wainer IW, Granvil CP, Wang T and Batist G (1994b) Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model. Cancer Res 54:4393-4397.
45. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH and Idle JR (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47:1157-1163.
46. Waxman DJ, Attisano C, Guengerich FP and Lapenson DP (1988) Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 243:424-436.
47. Weber GF and Waxman DJ (1993) Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochem Pharmacol 45:1685-1694.
48. Wheeler BM, Loehrer PJ, Williams SD and Einhorn LH (1986) Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4:28-34.
49. Wright JE (1997) Phosphoramide and oxazaphosphorine mustards, in Cancer Therapeutics: Experimental and Clinical Agents (Teicher BA ed) pp 23-79, Humana Press, Totowa, NJ.
50. Yang TJ, Krausz KW, Shou M, Yang SK, Buters JT, Gonzalez FJ and Gelboin HV (1998) Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol 55: 1633-1640.
51. Yu L and Waxman DJ (1996) Role of cytochrome P450 in oxazaphosphorine metabolism. Reactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab Dispos 24:1254-1262.
52. Yu LJ, Drewes P, Gustafsson K, Brain EGC, Hecht JED and Waxman DJ (1999) In vivo modulation of alternative pathways of P450-catalyzed cyclophosphamide metabolism: Impact on pharmacokinetics and antitumor activity. J Pharmacol Exp Ther 288:928-937.